|Avg Daily Vol (13 Wks)||2.34 Mil|
- Last trade 5/17/2013 4:00 PM ET
|Net Profit Margin||-165.25%|
|Market Cap||211.15 Mil|
|Shares Outstanding||137.11 Mil|
- * last 12 months
- InvestorPlace | 5/17/2013
- Peregrine Pharmaceuticals' Immunotherapy Bavituximab to Be Highlighted in Three Clinical Data Presentations at 2013 ASCO Annual MeetingMarketwire | 5/16/2013
- Motley Fool | 4/29/2013
- Peregrine Announces Completion of Patient Enrollment in Breast Cancer Clinical Trial for BavituximabMarketwire | 4/29/2013
- Seeking Alpha | 4/23/2013
- Seeking Alpha | 3/12/2013
- InvestorPlace | 3/11/2013
- Seeking Alpha | 12/10/2012
- Seeking Alpha | 9/10/2012
- Seeking Alpha | 7/16/2012
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Quotes delayed 15min, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations data provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.